Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study

Lancet

Volumn 355, Issue 9212, 2000, Pages 1303-1309

  Porte, Robert J ^a   Molenaar, I Quintus ^a   Begliomini, Bruno ^b   Groenland, Theo H N ^c   Januszkiewicz, Anna ^d   Lindgren, Leena ^e   Palareti, Gualtiero ^b   Hermans, Jo ^a   Terpstra, Onno T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM;

EID: 0034655629     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(00)02111-5     Document Type: Article

References (34)

1. Goldsmith M.F. Liver transplants. big business in blood JAMA. 250:1983;2904-2905.
2. Lewis J.H., Bontempo F.A., Cornell F.et al. Blood use in liver transplantation. Transfusion. 27:1987;222-225.
3. Deakin M., Gunson B.K., Dunn J.A.et al. Factors influencing blood transfusion during adult liver transplantation. Ann R Coll Surg Engl. 75:1993;339-344.
4. Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage during liver transpantation. Liver Transpl Surg. 3:1997;655-659.
5. Kindscher J. Blood usage in a newly organized liver transplant program. Transplant Proc. 25:1993;1823.
6. Bechstein W.O., Neuhaus P. A surgeon's perspective on the management of coagulation disorders before liver transplantation. Liver Transpl Surg. 3:1997;653-655.
7. Kozek-Langenecker S.A., Muller C.M., Felfernig M., Zimpfer M. Changes in hemostasis during orthotopic liver transplantation and massive transfusion. a case report Infsusionsther Transfusionsmed. 22:1995;296-300.
8. Mor E., Jennings L., Gonwa T.A., Holman M.J.et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet. 176:1993;219-227.
9. Miki C., Iriyama K., Gunson B.K., Mayer A.D., Buckels J.A., McMaster P. Influence of intraoperative blood loss on plasma levels of cytokines and endotoxin and subsequent graft liver function. Arch Surg. 132:1997;136-141.
10. Porte R.J. Coagulation and fibrinolysis in orthotopic liver transplantation. current views and insights Semin Thromb Hemost. 19:1993;191-196.
11. Porte R.J., Knot E.A., Bontempo F.A. Hemostasis in liver transplantation. Gastroenterology. 97:1989;488-501.
12. Kang Y.G., Martin D.J., Marquez J.et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg. 64:1985;888-896.
13. Porte R.J., Bontempo R.A., Knot F.A., Lewis J.H., Kang Y.G., Starzl T.E. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation. 47:1989;978-984.
14. Legnani C., Palareti G., Rodorigo G.et al. Protease activities, as well as plasminogen activators, contribute to the "lytic" state during orthotopic liver transplantation. Transplantation. 56:1993;568-572.
15. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 29:1985;236-261.
16. Bidstrup B.P., Royston D., Sapsford R.N., Taylor K.M. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 97:1989;364-372.
17. Dietrich W., Barankay A., Hahnel C., Richter J.A. High-dose aprotinin in cardiac surgery. three years' experience in 1,784 patients J Cardiothorac Vasc Anesth. 6:1992;324-327.
18. Mallett S.V., Cox D., Burroughs A.K., Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet. 336:1990;886-887.
19. Neuhaus P., Bechstein W.O., Lefebre B., Blumhardt G., Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet. 2:1989;924-925.
20. Shaw B.W. Jr., Martin D.J., Marquez J.M.et al. Advantages of venous bypass during orthotopic transplantation of the liver. Semin Liver Dis. 5:1985;344-348.
21. Grosse H., Lobbes W., Frambach M., Ringe B., Barthels M. Influence of high-dose aprotinin in hemostasis and blood requirement in orthotopic liver transplantation. Semin Thromb Hemost. 19:1993;302-305.
22. Groh J., Welte M., Azad S.C., Forst H., Pratschke E., Kratzer M.A. Does aprotinin affect blood loss in liver transplantation? Lancet. 340:1992;173.
23. Garcia Huete L., Domenech P., Sabate A., Martinez Brotons F., Jaurrieta E., Figueras J. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation. a randomized clinical study Hepatology. 26:1997;1143-1148.
24. Porte R.J., Molenaar I.Q. Aprotinin in liver transplantation. Hepatology. 27:1998;1169-1171.
25. Riess H., Jochum M., Machleidt W.et al. Possible role of extracellularly released phagocyte proteinases in coagulation disorder during liver transplantation. Transplantation. 52:1991;482-484.
26. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 55:1993;1033-1041.
27. Takei Y., Marzi I., Kaufmann F.C., Currin R.T., Lemasters J.J., Thurman R.G. Increase in survival time of liver transplants by protease inhibitors and a calcium channel blocker, nisoldipine. Transplantation. 50:1990;14-20.
28. Calmus Y., Cynober L., Dousset B.et al. Evidence for the detrimental role of proteolysis during liver preservation in humans. Gastroenterology. 108:1995;1510-1516.
29. Oldhafer J.H., Schuttler W., Wiehe B., Hauss J., Pichlmayr R. Treatment of preservation/reperfusion liver injury by the protease inhibitor aprotinin after cold ischemic storage. Transplant Proc. 23:1991;2380-2381.
30. Roberts R.F., Nichanian G.P., Carey J.N.et al. Addition of aprotinin in organ preservation solutions decreases lung reperfusion injury. Ann Thorac Surg. 66:1998;225-230.
31. Baubillier E., Cherqui D., Dominique C.et al. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation. 57:1994;1664-1666.
32. Rich J.B. The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg 66: S6-. 1998;11.
33. Lemmer J.H. Jr., Stanford W., Bonney S.L.et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg. 59:1995;132-136.
34. Bilbao I., Charco R., Balsells J.et al. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant. 12:1998;123-129.